AT
Akribion Therapeutics
The company develops a gene editing technology platform that utilizes RNA biomarkers for targeted cell depletion in cancer therapies. This approach enables early treatment for patients by precisely identifying and eliminating cancerous cells.
- Biotechnology
Updated 7 months ago
Funding
Funding rounds are not available yet.
Founders
Product
Features
- The company develops a gene editing technology platform that utilizes RNA biomarkers for targeted cell depletion in cancer therapies. This approach enables early treatment for patients by precisely identifying and eliminating cancerous cells.